Home Tags Antibody-drug conjugate

Tag: antibody-drug conjugate

SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...

Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...

Piramal Expands Its Grangemouth ADC Manufacturing Base

Piramal Healthcare UK Ltd., has invested £2.0 million into Scotland to expand its manufacturing base at Grangemouth. The Scottish facility, approved by the U.S. Food...

Treatment Response to Mirvetuximab Soravtansine Found to be Substantially Greater in...

Findings with mirvetuximab soravtansine (also known as IMGN853 and M9346A-sulfo-SPDB-DM4), a novel folate receptor alpha (FRα)-targeting antibody-drug conjugate being developed by ImmunoGen, a clinical-stage...

Phase II Trial of Denintuzumab Mafodotin Combination Therapy in Relapsed or...

A randomized phase II clinical trial of denintuzumab mafodotin, also known as SGN-CD19A (SGN-19A), in combination with the second-line salvage regimen of rituximab (Rituxan®;...

Phase II Clinical Trial of Brentuximab Vedotin Combination Therapy in...

Based on encouraging data in patients with CD30-expressing relapsed or refractory diffuse large B-cell lymphoma or DLBCL, the most common type of aggressive non-Hodgkin Lymphoma...

First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

Aspyrian’s Photoimmunotherapy based on the IRDye® 700 DX Platform Shows Efficacy...

A novel, highly specific, anticancer therapy called near infrared (NIR) photoimmunotherapy (PIT) that uses IRDye® 700DX, a phthalocyanine dye also known as IR700, has shown...

Initial Results from Phase I Trial with anti-HER2 ADC SYD985 Shows...

Researchers working for Dutch pharmaceutical company Synthon Biopharmaceuticals based in Nijmegen, The Netherlands, report positive initial results from the dose-escalation part of its ongoing first-in-human trial...

Analysis of Phase III AETHERA Data Demonstrates Brentuximab Vedotin Consolidation Therapy...

Several new analysis of Phase III data from the AETHERA trial (NCT01100502) demonstrate that brentuximab vedotin (Adcetris®; Seattle Genetics) consolidation therapy significantly extends progression-free...

Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...

Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...